Etiology, Pathophysiology, and Treatment of Atrial Fibrillation Part 1

被引:18
|
作者
Arortow, Wilbert S. [1 ]
机构
[1] New York Med Coll, Westchester Med Ctr, Div Cardiol, Dept Med, Valhalla, NY 10595 USA
关键词
atrial fibrillation; beta blockers; stroke; cardiovascular disease; cardioversion; digoxin; calcium channel blockers; radiofrequency catheter ablation; pacemakers; antiarrhythmic drugs;
D O I
10.1097/CRD.0b013e31816de1e3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Atrial fibrillation (AF) is associated with a higher incidence of mortality, stroke, and coronary events than is sinus rhythm. AF with a rapid ventricular rate may cause a tachycardia-related cardiomyopathy. Immediate direct-current cardioversion should be performed in patients with AF and acute myocardial infarction, chest pain due to myocardial ischemia, hypotension, severe heart failure, or syncope. Intravenous beta blockers, verapamil, or diltiazem may be given to immediately slow a very rapid ventricular rate in AF. An oral beta blocker, verapamil, or diltiazem should be used in persons with AF if a fast ventricular rate occurs at rest or during exercise despite digoxin. Amiodarone may be used in selected patients with symptomatic life-threatening AF refractory to other drugs. Digoxin should not be used to treat patients with paroxysmal AF. Nonpharmacologic therapies should be used in patients with symptomatic AF in whom a rapid ventricular rate cannot be slowed by drugs. This is part 1 of a 2-part review of the etiology, pathophysiology, and treatment of atrial fibrillation. The second part will be published in the subsequent issue of Cardiology in Review.
引用
收藏
页码:181 / 188
页数:8
相关论文
共 50 条
  • [21] Pathophysiology and treatment strategy for atrial fibrillation in patients with impaired LV function
    Ogawa, S
    JOURNAL OF CARDIAC FAILURE, 2005, 11 (09) : S267 - S267
  • [22] AGE-RAGE Stress in the Pathophysiology of Atrial Fibrillation and Its Treatment
    Prasad, Kailash
    INTERNATIONAL JOURNAL OF ANGIOLOGY, 2020, 29 (02) : 72 - 80
  • [23] Recent Insights into the Pathophysiology of Atrial Fibrillation
    Van Wagoner, David R.
    SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY, 2007, 19 (01) : 9 - 15
  • [24] Atrial fibrillation: Pathophysiology and current therapy
    Miyazaki, Shinsuke
    Shah, Ashok J.
    Scherr, Daniel
    Haissaguerre, Michel
    ANNALS OF MEDICINE, 2011, 43 (06) : 425 - 436
  • [25] Atrial Fibrillation Pathophysiology Implications for Management
    Iwasaki, Yu-ki
    Nishida, Kunihiro
    Kato, Takeshi
    Nattel, Stanley
    CIRCULATION, 2011, 124 (20) : 2264 - 2274
  • [26] Pathophysiology, epidemiology and complications of atrial fibrillation
    Perings, C
    Hennersdorf, M
    Vester, EG
    Weirich, J
    Strauer, BE
    INTERNIST, 1998, 39 (01): : 2 - 11
  • [27] Atrial Fibrillation: Pathophysiology and Therapeutic Options
    Bhatt, Himani V.
    Fischer, Gregory W.
    JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2015, 29 (05) : 1333 - 1340
  • [28] Epidemiology, etiology and mechanism of atrial fibrillation
    Le Fieuzey, Jean-Yves
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2011, 195 (4-5): : 953 - 960
  • [29] Etiology, Pathology, and Classification of Atrial Fibrillation
    Nayak, Srishti
    Natarajan, Balaji
    Pai, Ramdas G.
    INTERNATIONAL JOURNAL OF ANGIOLOGY, 2020, 29 (02) : 65 - 71
  • [30] Atrial fibrillation and type 2 diabetes: Prevalence, etiology, pathophysiology and effect of anti-diabetic therapies
    Bell, David S. H.
    Goncalves, Edison
    DIABETES OBESITY & METABOLISM, 2019, 21 (02): : 210 - 217